Two months after MSD (Merck & Co) set its eye on acquiring Eyebiotech (EyeBio), the former has closed the deal, making EyeBio its subsidiary.
MSD has acquired all outstanding shares of the privately held UK-based biotech through a subsidiary as part of the agreement. EyeBio’s shareholders will receive approximately $0.50 per share, totalling $1.3bn.
Following the acquisition, MSD has gained access to EyeBio’s lead asset Restoret (EYE-103), a tetravalent, tri-specific antibody that targets the Wingless-related integration site (Wnt) signalling pathway.
A Phase IIb/III trial investigating Restoret in patients with DME is expected to begin in H2 this year. In February, EyeBio reported positive data from the Phase Ib/IIa AMARONE trial (NCT05919693) in patients with treatment-naïve diabetic macular oedema (DME) and treatment-naive neovascular age-related macular degeneration (AMD).
In the study, Restoret improved vision in 26 participants with DME, leading to an improved best-corrected visual acuity by +11.2 letters and a mean reduction in retinal thickness of -143 µm. Similar outcomes were observed in the five treatment-naive neovascular AMD participants who received Restoret in combination with Regeneron Pharmaceuticals’ Eylea (aflibercept). The therapy was well tolerated, with no treatment-related adverse events.
In the past few months, MSD has invested considerable resources in expanding its therapeutics portfolio through acquisitions and partnerships. In March, MSD acquired US-based Harpoon Therapeutics to bolster its immunology pipeline. The company gained access to Harpoon’s T cell engagers – engineered antibodies that redirect T cells to attack cancer cells.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
In November 2023, the company acquired US-based Caraway Therapeutics to expand its pipeline for neurogenerative disease therapies. Caraway’s portfolio comprised a preclinical candidate that targets the transient receptor potential cation channel subfamily (TRPML1). The compound is being evaluated as a treatment for the lysosomal storage disorder, Gaucher disease, and glucocerebrosidase (GBA)-mutated Parkinson’s disease.
In October 2023, MSD signed a licensing agreement with Daiichi Sankyo to develop and commercialise three antibody-drug conjugate candidates.
